175 related articles for article (PubMed ID: 12041781)
1. Activity of roxithromycin against respiratory pathogens.
Facinelli B; Varaldo PE
J Chemother; 1991 Jan; 3 Suppl 1():33-5. PubMed ID: 12041781
[TBL] [Abstract][Full Text] [Related]
2. [In vitro activity of roxithromycin, new semisynthetic macrolide against obligate anaerobes].
Dubreuil L; Devos J; Romond C; Bryskier A
Pathol Biol (Paris); 1986 May; 34(5):440-4. PubMed ID: 3534717
[TBL] [Abstract][Full Text] [Related]
3. [Comparative in vitro bacteriostatic and bactericidal effect of 5 macrolides: roxithromycin, erythromycin, oleandomycin, josamycin and spiramycin against 284 hospital bacterial strains].
Le Noc P; Croize J; Bryskier A; Le Noc D; Robert J
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):553-9. PubMed ID: 2797879
[TBL] [Abstract][Full Text] [Related]
4. [Multicenter study of the clinical efficacy and tolerance of roxithromycin compared to erythromycin ethylsuccinate in lower respiratory tract infections].
Bertrand A; Jonquet O; Sauvaget J
Pathol Biol (Paris); 1988 May; 36(5):544-7. PubMed ID: 3043354
[TBL] [Abstract][Full Text] [Related]
5. [In vitro sensitivity of Mycobacterium avium and Mycobacterium xenopi to erythromycin, roxithromycin and doxycycline].
Maugein J; Fourche J; Mormede M; Pellegrin JL
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):565-7. PubMed ID: 2797881
[TBL] [Abstract][Full Text] [Related]
6. [Erythromycin resistance of group A beta-hemolytic streptococci isolated from patients with upper respiratory tract infections].
Yazgi H; Ertek M; Aktaş AE
Mikrobiyol Bul; 2002 Jan; 36(1):11-4. PubMed ID: 12476761
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of skin-colonizing S. aureus strains in children with atopic dermatitis.
Hoeger PH
Pediatr Allergy Immunol; 2004 Oct; 15(5):474-7. PubMed ID: 15482526
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro and in vivo efficacy of roxithromycin and erythromycin against a strain of methicillin-susceptible Staphylococcus epidermidis.
Danias PG; Chalevelakis G; Mylonakis EE; Argyropoulou A; Paniara O; Saroglou G; Raptis SA
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):51-4. PubMed ID: 9791758
[TBL] [Abstract][Full Text] [Related]
9. The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis.
Brett M; Short P; Beatson S
J Antimicrob Chemother; 1998 Mar; 41 Suppl B():23-7. PubMed ID: 9579709
[TBL] [Abstract][Full Text] [Related]
10. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
11. [Susceptibility to roxithromycin of gram-positive cocci isolated from patients with lowered immunity].
Mróz E; Podolak-Dawidziak M; Grzybek-Hryncewicz K; Dworniczek E
Med Dosw Mikrobiol; 1994; 46(1-2):5-8. PubMed ID: 7967928
[TBL] [Abstract][Full Text] [Related]
12. [The effect of subinhibitory concentrations of norfloxacin, erythromycin and roxithromycin on Pseudomonas aeruginosa virulence factors].
Hostacká A
Epidemiol Mikrobiol Imunol; 1995 Sep; 44(3):115-7. PubMed ID: 7489133
[TBL] [Abstract][Full Text] [Related]
13. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
15. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
Inoue M; Kohno S; Kaku M; Yamaguchi K; Igari J; Yamanaka K
Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
Pottumarthy S; Fritsche TR; Sader HS; Stilwell MG; Jones RN
Int J Antimicrob Agents; 2005 Apr; 25(4):282-9. PubMed ID: 15784306
[TBL] [Abstract][Full Text] [Related]
17. [The Viriato Study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2001 and 2002].
Melo-Cristino J; Serrano N;
Rev Port Pneumol; 2003; 9(4):293-310. PubMed ID: 19771688
[TBL] [Abstract][Full Text] [Related]
18. [In vitro susceptibility of streptococcus pneumoniae strains isolated from lower respiratory infections in Instituto Nacional del Tórax (INT)].
Soler T; Salamanca L; Arbo G; Molina E
Rev Med Chil; 2002 Mar; 130(3):304-8. PubMed ID: 12043373
[TBL] [Abstract][Full Text] [Related]
19. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
Sahm DF; Brown NP; Draghi DC; Evangelista AT; Yee YC; Thornsberry C
Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
